Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study

Fanouriakis, Antonis; Adamichou, Christina; Koutsoviti, Sofia; Panopoulos, Stylianos; Staveri, Chrysanthi; Klagou, Anastasia; Tsalapaki, Christina; Pantazi, Lamprini; Konsta, Styliani; Mavragani, Clio; Dimopoulou, Despoina; Ntali, Styliani; Katsikas, Georgios; Boki, Kyriaki; Vassilopoulos, Dimitrios; Konstantopoulou, Pinelopi; Liossis, Stamatis-Nick; Elezoglou, Antonia; Tektonidou, Maria; Sidiropoulos, Prodromos; ERDEN, ABDULSAMET; Sfikakis, Petros; Bertsias, George; Boumpas, Dimitrios

doi:10.1016/j.semarthrit.2018.02.014

Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study

Copy For Citation

Fanouriakis A., Adamichou C., Koutsoviti S., Panopoulos S., Staveri C., Klagou A., ...More

SEMINARS IN ARTHRITIS AND RHEUMATISM, vol.48, no.3, pp.467-474, 2018 (SCI-Expanded)

Publication Type: Article / Review
Volume: 48 Issue: 3
Publication Date: 2018
Doi Number: 10.1016/j.semarthrit.2018.02.014
Journal Name: SEMINARS IN ARTHRITIS AND RHEUMATISM
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.467-474
Hacettepe University Affiliated: Yes

Abstract

Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.